rs1057519864
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
CDK4/6i was also effective in prostate tumor models expressing the AR-V7 variant or the AR F876L mutation, both of which are associated with treatment resistance.
|
28209757 |
2017 |
rs1057519912
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
So far, the recently reported MED12 p.L1224F mutation could not be validated in our unselected cohort of prostate tumours.
|
23661306 |
2013 |
rs1057519971
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
We sequenced the SPOP gene to identify somatic mutations in 49 AA prostate tumors and identified three missense mutations (p.Y87C, p.F102S, and p.G111E) in five AA prostate tumors (10%) and one synonymous variant (p.I106I) in one tumor.
|
24994784 |
2015 |
rs1060501201
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers.
|
28186998 |
2017 |
rs113488022
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
In the course of modeling malignant melanoma in a tyrosinase promoter transgenic system, we developed a genetically-engineered mouse (GEM) model of invasive prostate cancers, whereby an activating mutation of BRAF(V6</span>00E)--a mutation found in approximately 10% of human prostate tumors--was targeted to the epithelial compartment of the prostate gland on the background of Ink4a/Arf deficiency.
|
19079609 |
2008 |
rs1197734477
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers.
|
28186998 |
2017 |
rs121913377
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
In the course of modeling malignant melanoma in a tyrosinase promoter transgenic system, we developed a genetically-engineered mouse (GEM) model of invasive prostate cancers, whereby an activating mutation of BRAF(V6</span>00E)--a mutation found in approximately 10% of human prostate tumors--was targeted to the epithelial compartment of the prostate gland on the background of Ink4a/Arf deficiency.
|
19079609 |
2008 |
rs137852581
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
CWR22Rv1 (22Rv1) is an androgen-responsive human prostate carcinoma cell line derived from a primary prostate tumor that expresses mutant (H874Y) androgen receptors (AR) and secretes low levels of prostate specific antigen (PSA).
|
15249132 |
2004 |
rs148609049
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
It was found to be an eQTL for ANO7 (Linear model p-values for Finnish patients p = 0.009; Camcap prostate tumor p = 2.53E-06; Stockholm prostate tumor cohort p = 1.53E-13). rs148609049 was not associated with risk, but was related to shorter survival (HR 1.56; 95% CI 1.03-2.36).
|
30157291 |
2018 |
rs1512268
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Genome-wide association studies (GWAS) identified multiple susceptible loci for prostate cancer (PC), and recent GWAS implicated that a common variant rs1512268 on chromosome 8p21 is associated with PC susceptibility, which is located at 14 kb downstream of a prostate tumor suppressor gene NKX3.1.
|
20716579 |
2010 |
rs1571801
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis of the distribution of these SNPs among 1032 prostate cancer patients and 571 control subjects of European descent indicated that one, rs1571801, located in the DAB2IP gene, which encodes a novel Ras GTPase-activating protein and putative prostate tumor suppressor, was associated with aggressive prostate cancer (one-sided P value = .004).
|
18073375 |
2007 |
rs16861209
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue.
|
21960694 |
2011 |
rs17366568
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue.
|
21960694 |
2011 |
rs182052
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue.
|
21960694 |
2011 |
rs2155222
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
The findings indicate the functionality of the PrCa death-predisposing SNPs rs143975731, rs12277366, rs2155225, and rs2155222 as DGAT2 regulators in prostate tumors.© 2016 Wiley Periodicals, Inc.
|
27113481 |
2016 |
rs266729
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue.
|
21960694 |
2011 |
rs28909982
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
In this study, we have identified two novel somatic CHEK2 mutations, c.349A > G (p.R117G) and c.967A > C (p.E321K), in prostate tumor specimens and investigated the functions of these mutants in vivo.
|
16835864 |
2006 |
rs339331
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Finally, we observe a significant association between the risk-associated T allele at rs339331 and increased RFX6 mRNA levels in human prostate tumors.
|
24390282 |
2014 |
rs368234815
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
We show that the <i>IFNL4</i> rs368234815-ΔG allele was significantly associated with IRDS in prostate tumors and overall survival of AA patients.
|
30012562 |
2018 |
rs375118292
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis of the prostate tumor from this individual verified the presence of heterozygous N296I as well as an ERG fusion.
|
24796539 |
2014 |
rs3774261
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue.
|
21960694 |
2011 |
rs587782480
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
In this study, we have identified two novel somatic CHEK2 mutations, c.349A > G (p.R117G) and c.967A > C (p.E321K), in prostate tumor specimens and investigated the functions of these mutants in vivo.
|
16835864 |
2006 |
rs727502792
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis of the prostate tumor from this individual verified the presence of heterozygous N296I as well as an ERG fusion.
|
24796539 |
2014 |
rs746001963
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis of the prostate tumor from this individual verified the presence of heterozygous N296I as well as an ERG fusion.
|
24796539 |
2014 |
rs7639352
|
|
Prostatic Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue.
|
21960694 |
2011 |